-

Bristol Myers Squibb to Participate in Upcoming Investor Conferences

NEW YORK--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the following investor conferences in June 2023:

Company executives will take part in a fireside chat at the 2023 Jefferies Healthcare Conference in New York, New York on June 8, 2023. They will answer questions about the company at 9:00 a.m. ET.

Bristol Myers Squibb executives will also participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023, in Dana Point, California. They will answer questions about the company at 8:40 a.m. PT/11:40 a.m. ET.

Investors and the general public are invited to listen to a live webcast of both sessions during their respective times at http://investor.bms.com. An archived edition of each session will be available later the same day it occurs.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

corporatefinancial-news

Contacts

Bristol Myers Squibb

Media:
media@bms.com

Investor Relations:
investor.relations@bms.com

Bristol Myers Squibb

NYSE:BMY

Release Summary
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
Release Versions
$Cashtags

Contacts

Bristol Myers Squibb

Media:
media@bms.com

Investor Relations:
investor.relations@bms.com

More News From Bristol Myers Squibb

Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline

PRINCETON, N.J.--(BUSINESS WIRE)--BMS to Unveil New Data at ASCO 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline...

Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across Its Global Operations

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across......

Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults...
Back to Newsroom